Investieren in Zeiten hoher Inflation: Partizipieren Sie an Unternehmen, die sich im Umfeld steigender Preise besser behaupten können - Mehr erfahren!-w-
20.05.2022 19:08

Top Research Reports for JPMorgan, Gilead Sciences & CSX

Folgen
Werbung
Friday, May 20, 2022The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corp. (CSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>> JPMorgan shares have declined -24.2% in the year-to-date period against the Zacks Banks - Major Regional industry’s decline of -19.1%. The company’s first-quarter 2022 results show loan growth, the dismal performance of the capital markets business, and higher provisions. The volatile nature of the trading business is likely to make fee income growth tough. Relatively lower interest rates in the near term are expected to keep weighing on the company’s margins and interest income. Steadily rising expenses remain a key near-term headwind. However, Opening new branches, strategic acquisitions/investments, global expansion and digitization initiatives and decent investment banking (IB) pipeline are likely to keep aiding the company's financials. Its steady capital deployments look sustainable and will enhance shareholder value. (You can read the full research report on JPMorgan here >>>) Gilead Sciences shares have declined -3.7% over the past year against the Medical - Biomedical and Genetics industry’s decline of -37.7%. The Zacks analyst believes that the loss of Atripla and Truvada’s exclusivity is affecting sales. Although the CAR T cell therapy franchise, comprising Yescarta and Tecartus, is gaining traction, it has a long way to go before contributing meaningfully. Never the less, the company’s flagship HIV therapy Biktarvy continues to register growth and gains in market share. It is looking to solidify its oncology franchise. The acquisition of Immunomedics added an approved drug Trodelvy to its portfolio, and the label expansion of the drug should boost sales. Increased contribution from the COVID-19 treatment, Veklury boosted performance. The recent surge in cases in many countries might drive sales further. (You can read the full research report on Gilead Sciences here >>>) CSX shares have declined -5.5% over the past year against Transportation - Rail industry’s decline of -5.9%. The Zacks analyst believes that supply chain disruptions are hurting the company’s operations. Weakness in the merchandise segment due to lower automotive volumes is concerning. High costs, primarily due to escalating fuel expenses, pose a threat to CSX’s bottom line. The company’s high capital expenditures are also worrisome. Due to these headwinds, shares of the company have lost 17.7% in the year-to-date period. However, due to a healthy freight environment, CSX is benefiting from higher export coal volumes, domestic intermodal shipments, and favorable pricing. With the demand scenario expected to remain strong, management anticipates double-digit growth in operating income and revenues for 2022 from the respective year-ago reported figures. The company’s measures to reward shareholders are encouraging as well. In February, CSX hiked its dividend by 7.5%.(You can read the full research report on CSX here >>>) Other noteworthy reports we are featuring today include CVS Health Corp. (CVS), The Progressive Corp. (PGR), and China Petroleum & Chemical Corp. (SNP).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadBranch Expansion Efforts Aid JPMorgan (JPM) Amid Low RatesBiktarvy, Veklury Fuels Gilead (GILD) As Core Business SlowsHealthy Freight Demand Aids CSX Amid Supply Chain WoesFeatured ReportsCVS Health (CVS) Pharmacy Business Grows Amid Stiff RivalryThe Zacks analyst is impressed with CVS Health's growth in pharmacy revenues on higher pharmacy claims volume, rise in specialty pharmacy and brand inflation. Yet, stiff rivalry remains a concern.Progressive's (PGR) Solid Policies in Force Aid, Cat Loss AilPer the Zacks analyst, Progressive is set to grow on, solid policies in force, competitive rates and leadership position. However, cat loss exposure inducing underwriting volatility ails.Sinopec (SNP) Banks on Shengli Geological Shale Oil ReservesThe Zacks analyst is impressed by Sinopec's discovery of 458 million tons of shale oil reserves at its Shengli field, which will drive the production. Yet, rising exploration costs remain concerning.Intercontinental (ICE) Banks on Buyouts & Solid Balance Sheet Per the Zacks analyst, Intercontinental Exchange is set to grow on a number of acquisitions and cost synergies. Moreover, a solid balance sheet provides financial flexibility. Solid Investments Aid Sempra Energy (SRE), Weak Solvency WoePer the Zacks analyst, systematic investments significantly boost Sempra Energy's infrastructure and its customers reliability. However, its weak solvency position remains a concernSynopsys (SNPS) Banks on Strong Product Menu, Contract WinsPer the Zacks analyst, Synopsys' focus on strengthening its product portfolio is helping it cater to the growing demand in the EDA market. Deal wins at leading semiconductor companies is a tailwind.Ericsson (ERIC) Rides on Comprehensive 5G Portfolio StrengthPer the Zacks analyst, Ericsson is likely to benefit from its comprehensive 5G product portfolio as it focuses on structural changes to generate efficiency gains and boost cost competitiveness.New UpgradesFocus on Permian Basin, Cost Management Aid Occidental (OXY)Per the Zacks analyst Occidental's efficient cost management and expansion of its operation Permian Basin through acquisition of Anadarko will drive its performance over the long run.Nutrien (NTR) Gains on Strong Demand and Higher Prices Per the Zacks analyst, the company will gain from solid demand for fertilizers driven by the strength in global agriculture markets. Higher prices for crop nutrients will also support its margins.Marriott (MAR) Likely to Gain From Robust Expansion EffortsThe Zacks analyst believes that Marriott's efforts to expand its footprint and improving demand bode well. At the end of first-quarter 2022, Marriott's development pipeline totaled nearly 2,878 hotelsNew DowngradesWalmart (WMT) Hurt by Cost Inflation, Supply-Chain HurdlesPer the Zacks analyst, Walmart is battling supply-chain hurdles, and fuel and wage cost inflation. Walmart expects some of these woes to persist, and lowered earnings per share view for fiscal 2023.Soft Hard Seltzer Ail Boston Beer's (SAM) PerformancePer the Zacks analyst, Boston Beer has been reeling under slowed growth trends in hard seltzer for some time now. As a result, Q1 revenues declined 21.1% year over year.Declining Sales, Rising Costs Irk Align Technology (ALGN)The Zacks analyst is apprehensive about Align Technology's declining clear aligner revenues. Also, escalating operating expenses are building significant pressure on the bottom line. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report CSX Corporation (CSX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report China Petroleum & Chemical Corporation (SNP): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report To read this article on Zacks.com click here.
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf CSX Corp.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CSX Corp.
Long
Short
Hebel wählen:
5x
10x
Name
Hebel
KO
Emittent
Quelle: Zacks

Nachrichten zu JPMorgan Chase & Co.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu JPMorgan Chase & Co.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
25.05.2022JPMorgan ChaseCo OutperformCredit Suisse Group
23.05.2022JPMorgan ChaseCo OverweightBarclays Capital
18.05.2022JPMorgan ChaseCo OutperformCredit Suisse Group
17.05.2022JPMorgan ChaseCo OverweightBarclays Capital
19.04.2022JPMorgan ChaseCo SellJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
25.05.2022JPMorgan ChaseCo OutperformCredit Suisse Group
23.05.2022JPMorgan ChaseCo OverweightBarclays Capital
18.05.2022JPMorgan ChaseCo OutperformCredit Suisse Group
17.05.2022JPMorgan ChaseCo OverweightBarclays Capital
14.04.2022JPMorgan ChaseCo OutperformCredit Suisse Group
14.02.2022JPMorgan ChaseCo HoldJefferies & Company Inc.
14.07.2020JPMorgan ChaseCo NeutralGoldman Sachs Group Inc.
02.04.2020JPMorgan ChaseCo HoldDeutsche Bank AG
22.07.2019JPMorgan ChaseCo NeutralGoldman Sachs Group Inc.
28.06.2019JPMorgan ChaseCo HoldDeutsche Bank AG
19.04.2022JPMorgan ChaseCo SellJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
18.10.2021JPMorgan ChaseCo SellJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
03.08.2017JPMorgan ChaseCo SellJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
21.12.2012JPMorgan ChaseCo verkaufenJMP Securities LLC
21.09.2007Bear Stearns sellPunk, Ziegel & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für JPMorgan Chase & Co. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Ukraine-Krieg im Ticker: DAX freundlich -- Asiens Börsen schließen im Plus -- Siemens Healthineers startet Aktienrückkauf -- Zahlungsausfall bei Russland eingetreten -- Nike im Fokus

Siemens übernimmt Softwareanbieter Brightly für Milliardenbetrag. Siltronic platziert nachhaltiges Schuldscheindarlehen in Millionenhöhe. Stresstest bestanden: Morgan Stanley, Goldman Sachs & Co. steigern Aktienrückkäufe und Dividenden.

Umfrage

Goldpreis im Fokus der Anleger: Sind Sie in Gold investiert?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln